KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to $439.7 million.

  • Alnylam Pharmaceuticals' Other Non-Current Liabilities rose 2300.09% to $439.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $439.7 million, marking a year-over-year increase of 2300.09%. This contributed to the annual value of $393.1 million for FY2024, which is 2746.13% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Other Non-Current Liabilities of $439.7 million as of Q3 2025, which was up 2300.09% from $407.5 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Other Non-Current Liabilities registered a high of $439.7 million during Q3 2025, and its lowest value of $60.5 million during Q1 2021.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Other Non-Current Liabilities value was $257.1 million (recorded in 2023), while the average stood at $249.6 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Other Non-Current Liabilities soared by 55732.77% in 2021 and then skyrocketed by 1629.64% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $99.0 million in 2021, then soared by 114.81% to $212.6 million in 2022, then soared by 45.09% to $308.4 million in 2023, then increased by 27.46% to $393.1 million in 2024, then grew by 11.84% to $439.7 million in 2025.
  • Its Other Non-Current Liabilities was $439.7 million in Q3 2025, compared to $407.5 million in Q2 2025 and $422.4 million in Q1 2025.